Data on patients with type 2 diabetes and acute coronary syndrome revealed those who took aleglitazar attained significant reductions in A1C and required less insulin treatment at three months than those in the placebo arm. However, patients in the aleglitazar group showed higher rates of heart failure, renal dysfunction and gastrointestional hemorrhage and did not gain cardiovascular benefits compared with the controls. The trial was terminated early. The findings were presented at the American College of Cardiology meeting and published in the Journal of the American Medical Association.
Published in Brief: